Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Xanomeline And Trospium · Cobenfy

Small molecule · Agonist of M1 muscarinic acetylcholine receptor (CHRM1) and M4 muscarinic acetylcholine receptor (CHRM4) · developed by Bristol-Myers

Approved FDA, Sep 2024

BMY Developer

2 Registered trials

What is Xanomeline And Trospium?

Xanomeline and trospium is a combination of a muscarinic agonist and antagonist. Xanomeline acts as an agonist at M1 and M4 muscarinic acetylcholine receptors in the central nervous system, while trospium antagonizes muscarinic receptors primarily in peripheral tissues.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Cobenfy, KarXT
Drug type: Small molecule
Targets: M1 muscarinic acetylcholine receptor (CHRM1), M4 muscarinic acetylcholine receptor (CHRM4), muscarinic receptors (secondary target)
Mechanism: Agonist of M1 muscarinic acetylcholine receptor (CHRM1) and M4 muscarinic acetylcholine receptor (CHRM4)
Therapy area: Psychiatry
Developer: Bristol-Myers (BMY)
FDA status: Approved as Cobenfy (September 26, 2024), NDA216158 · FDA label

✅ FDA-approved uses

Schizophrenia in adults

From the indications section of the FDA label (version of Jan 16, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06951711	Phase 3	Bipolar Disorder Type I With Mania or Mania With Mixed Features	Recruiting	BMY
NCT07101094	N/A	Schizophrenia	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

Other drugs acting on CHRM1 / CHRM4

Xanomeline FDA approved KarX-EC Phase 3

More from Bristol-Myers

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Xanomeline And Trospium

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z